27-June-2019: The global antinuclear antibody test market size
is expected to reach USD 2.36 billion by 2025, according to a new report by
Grand View Research, Inc. It is anticipated to expand at a CAGR of 12.5% over
the forecast period. Rising adoption of ANA test coupled with government
initiatives to treat autoimmune disorders is likely to drive the market.
Furthermore, rising incidence of autoimmune disorders is projected to fuel the
growth.
Antinuclear Antibody (ANA) testing is an important tool to diagnose and manage autoimmune diseases such as Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis. According to the Lupus Foundation of America, at least 5 million people globally and around 1.5 million people in U.S. have a form of lupus. Around 16,000 new cases are registered every year. The disease mostly affects women of childbearing age. SLE accounts for almost 70% of all cases of lupus. The high prevalence of autoimmune disorders is one of the factors driving the market.
Antinuclear Antibody (ANA) testing is an important tool to diagnose and manage autoimmune diseases such as Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis. According to the Lupus Foundation of America, at least 5 million people globally and around 1.5 million people in U.S. have a form of lupus. Around 16,000 new cases are registered every year. The disease mostly affects women of childbearing age. SLE accounts for almost 70% of all cases of lupus. The high prevalence of autoimmune disorders is one of the factors driving the market.
Extension of ANA from a test
for SLE to a test for any autoimmune diseases has boosted the usage of
antinuclear antibody testing. An increase in ANA demand may also be due to the
factors such as expanded role of primary care physicians in healthcare delivery
systems. In addition, rising R&D activities and government initiatives
regarding early diagnosis of autoimmune disorders have triggered the demand for
ANA tests.
In
depth research report on Antinuclear Antibody (ANA) Test Market
Further
key findings from the study suggest:
· Reagents
and assay kits was the largest segment in 2017. It is likely to witness fastest
growth over the forecast period due to wide usage and rise in a number of reagent
rental agreements
· Immunofluorescence
assay led the market in terms of market share in 2017 owing to superior
sensitivity compared to other available techniques
· ELISA
is expected to be the fastest growing segment over the forecast period.
Increasing adoption of these tests is attributed to easy automation and
handling without high level of operator skill
· Rheumatoid
arthritis segment is projected to hold largest market share, mainly due to high
prevalence of the disease
· North
America was the largest region in terms of revenue in 2017, followed by Europe.
Both are the most well-established regions in terms of the adoption of ANA
testing and make up most of the existing market
· Asia
Pacific is likely to be the fastest growing region over the forecast period due
to unmet clinical needs and need for better diagnosis. Rising government
initiatives and clinical research activities for advanced diagnostics are
expected to further fuel growth
· Key
players operating in the antinuclear antibody test market are Thermo Fisher
Scientific Inc.; Alere Inc.; Bio-Rad Laboratories; Trinity Biotech PLC; Zeus
Scientific, Inc.; Inova Diagnostics; Immuno Concepts; Erba Diagnostics, Inc.;
Euroimmun AG; and Antibodies Inc.
· Key
companies are adopting R&D, geographic expansion, and collaborations to
gain market share.
Grand View Research has
segmented the global antinuclear antibody test market on the basis of product,
technique, application, end use, and region:
Antinuclear
Antibody Test Product Outlook (Revenue, USD Million, 2014 - 2025)
· Reagents
& Assay Kits
· Systems
· Software
& Services
Antinuclear
Antibody Test Technique Outlook (Revenue, USD Million, 2014 - 2025)
· ELISA
· Immunofluorescence
Assay
· Multiplex
Assay
Antinuclear
Antibody Test Application Outlook (Revenue, USD Million, 2014 - 2025)
· Rheumatoid
Arthritis
· Systemic
Lupus Erythematosus
· Sjogren’s
Syndrome
· Scleroderma
· Others
Antinuclear
Antibody Test End-use Outlook (Revenue, USD Million, 2014 - 2025)
· Hospitals
· Clinical
Laboratories
· Physician
Office Laboratories
· Others
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment